Imugene names new advisory board members
This article was originally published in Scrip
Australian biopharmaceutical company Imugene, which develops oncology drugs, has appointed Professor Dr Christoph Zielinski and Professor Dr Ursula Wiedermann to its scientific advisory board. Professor Zielinski is the director of the clinical division of oncology and chair of the department of medicine at the Medical University of Vienna, Austria. He is also coordinator of the comprehensive cancer centre at the university and the General Hospital in Vienna and is president of the Central European Cooperative Oncology Group (CECOG). Meanwhile, Professor Wiedermann is professor of vaccinology and head of the institute of specific prophylaxis and tropical medicine of the Medical University Vienna.
You may also be interested in...
The Scrip 100 universe gathers FY 2019 financial performance data and compares the activities of the Top 100 biopharma businesses, ranked by pharma sales. Here In Vivo breaks out the Top 10 in the league table. Which big pharma holds the top spot this year?
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.